Document Detail

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
MedLine Citation:
PMID:  17461848     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Patients heterozygous for the C-C chemokine receptor 5 (CCR5) Delta32 deletion spontaneously progress less rapidly to AIDS and death than do wild-type patients. We investigated whether the CCR5 Delta32 deletion has an impact on immunological, virological and clinical responses to highly active antiretroviral therapy (HAART) in HIV-1-infected patients. PATIENTS AND METHODS: We included in the study 565 HIV-1-infected patients from the French HIV-1 infected cohort with documented date of seroconversion (SEROCO)/haemophiliacs HIV-1 infected (HEMOCO) cohorts, who started HAART after 1996. We investigated virological responses to HAART at 6 months (defined as a plasma HIV-1 RNA measurement below the threshold of detection or a 2 log HIV-1 RNA decrease) and at 12 months (defined as a plasma HIV-1 RNA measurement below the threshold of detection) and clinical response to HAART by Kaplan-Meier survival curves, with AIDS and death as outcomes. RESULTS: The Delta32 heterozygous patients (n=83; 15%) had a better virological response to HAART than wild-type patients (73 vs 53% at 6 months, P=0.01; and 60 vs 44% at 12 months, P=0.01). This better virological response was still observed after adjustment for antiretroviral status (whether or not patients were naïve to antiretroviral therapy), year of HAART initiation, number of new antiretroviral drugs and baseline viral load. There was no statistical difference between heterozygous patients and wild-type patients in terms of survival and AIDS-free survival. CONCLUSIONS: CCR5 Delta32 heterozygous patients were more likely to have a virological response to HAART than wild-type patients at 6 and 12 months. However, this virological response did not produce better immunological and clinical responses. The long-term impact of the Delta32 deletion on survival in HIV-1-infected treated patients should be investigated in a meta-analysis.
J J Laurichesse; A Persoz; I Theodorou; C Rouzioux; J F Delfraissy; L Meyer
Related Documents :
20856068 - Silent period-dentate, edentulous, and patients with craniomandibular dysfunction.
15030338 - Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for ne...
9776468 - Saccadic slowing in myotonic dystrophy and ctg repeat expansion.
8615718 - Technical considerations in endoscopic cervicothoracic sympathectomy.
10638948 - Increased mortality in hemodialyzed patients with elevated serum troponin t: a one-year...
16142858 - Histological patterns of synovitis and serum chemokines in patients with rheumatoid art...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  HIV medicine     Volume:  8     ISSN:  1464-2662     ISO Abbreviation:  HIV Med.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-27     Completed Date:  2007-12-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897392     Medline TA:  HIV Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  213-9     Citation Subset:  IM    
INSERM, U569, Hôpital Bicêtre, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiretroviral Therapy, Highly Active / methods*
CD4 Lymphocyte Count
Cohort Studies
DNA / chemistry,  genetics
Gene Deletion
HIV Infections / drug therapy*,  genetics,  immunology,  virology
HIV-1 / growth & development*
Longitudinal Studies
Polymerase Chain Reaction
RNA, Viral / blood
Receptors, CCR5 / genetics*,  immunology
Viral Load
Reg. No./Substance:
0/RNA, Viral; 0/Receptors, CCR5; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of lif...
Next Document:  Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving ...